InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.740
-0.090 (-4.92%)
Feb 24, 2025, 11:53 AM EST - Market open
InflaRx Employees
InflaRx had 62 employees as of December 31, 2023. The number of employees increased by 18 or 40.41% compared to the previous year.
Employees
62
Change (1Y)
18
Growth (1Y)
40.41%
Revenue / Employee
$3,021
Profits / Employee
-$1,019,980
Market Cap
102.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
IFRX News
- 5 days ago - InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 10 days ago - InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 10 days ago - InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 4 weeks ago - InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 5 weeks ago - InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS) - GlobeNewsWire
- 2 months ago - InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewsWire
- 3 months ago - InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome - GlobeNewsWire
- 3 months ago - InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire